1. Hauptnavigation
  2. Navigation des Hauptbereiches
  3. Inhalt der Seite

Ausgewählte Publikationen der Abteilung

Natural killer cells prevent infectious mononucleosis symptoms.
Chijoke O, Lipmann A, Feederle R, Barros MHM, Krieg C, Marcenaro E, Antsiferova O, Landtwing V, Bossart W, Moretta A, Hassan R, Boyman O, Niedobitek G, Delecluse HJ, Capaul R, Muenz C.
Cell Rep 2013 Dec 25;5(6):1489-98.

Genetics of Epstein-Barr virus microRNAs.
Klinke O, Feederle R, Delecluse HJ.
Semin Cancer Biol. 2014 Mar 3. pii: S1044-579X(14)00026-1.

Spontaneous lytic replication and epitheliotropism define an epstein-barr virus strain found in carcinomas.
Tsai MH, Raykova A, Klinke O, Bernhardt K, Gärtner K, Leung CS, Geletneky K, Sertel S, Münz C, Feederle R, Delecluse HJ.
Cell Rep. 2013 Oct 31;5(2):458-70

Latency of Epstein-Barr virus is disrupted by gain-of-function mutant cellular AP-1 proteins that preferentially bind methylated DNA.
Yu KP, Heston L, Park R, Ding Z, Wang'ondu R, Delecluse HJ, Miller G.
Proc Natl Acad Sci U S A. 2013 May 14;110(20):8176-81. doi: 10.1073/pnas.1301577110. Epub 2013 Apr 26.
 
A cluster of virus-encoded microRNAs accelerates acute systemic Epstein-Barr virus infection but does not significantly enhance virus-induced oncogenesis in vivo.
Wahl A, Linnstaedt SD, Esoda C, Krisko JF, Martinez-Torres F, Delecluse HJ, Cullen BR, Garcia JV.
J Virol. 2013 May;87(10):5437-46. doi: 10.1128/JVI.00281-13. Epub 2013 Mar 6.
 
An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA.
Pavlova S, Feederle R, Gärtner K, Fuchs W, Granzow H, Delecluse HJ.
J Virol. 2013 Feb;87(4):2011-22. doi: 10.1128/JVI.02533-12. Epub 2012 Dec 12.

Epstein-Barr virus infection of naïve B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology.
Heath E, Begue-Pastor N, Chaganti S, Croom-Carter D, Shannon-Lowe C, Kube D, Feederle R, Delecluse HJ, Rickinson AB, Bell AI.
PLoS Pathog. 2012 May;8(5):e1002697. Epub 2012 May 10.

The viral and cellular microRNA targetome in lymphoblastoid cell lines.
Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, Hafner M, Nusbaum JD, Feederle R, Delecluse HJ, Luftig MA, Tuschl T, Ohler U, Cullen BR.
PLoS Pathog. 2012 Jan;8(1):e1002484. Epub 2012 Jan 26.

EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription.
Tsai K, Thikmyanova N, Wojcechowskyj JA, Delecluse HJ, Lieberman PM.
PLoS Pathog. 2011 Nov;7(11):e1002376. Epub 2011 Nov 10.

The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes.
Feederle R, Haar J, Bernhardt K, Linnstaedt SD, Bannert H, Lips H, Cullen BR, Delecluse HJ.
J Virol. 2011 Oct;85(19):9801-10. Epub 2011 Jul 13.

A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus.
Feederle R, Linnstaedt SD, Bannert H, Lips H, Bencun M, Cullen BR, Delecluse HJ.
PLoS Pathog. 2011 Feb;7(2):e1001294. Epub 2011 Feb 17.

The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways.
Zuo J, Quinn LL, Tamblyn J, Thomas WA, Feederle R, Delecluse HJ, Hislop AD, Rowe M.
J Virol. 2011 Feb;85(4):1604-14. Epub 2010 Dec 1.

Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus.
Iskra S, Kalla M, Delecluse HJ, Hammerschmidt W, Moosmann A.
J Virol. 2010 Apr;84(7):3612-23. Epub 2010 Jan 20.

Epstein-Barr virus genetics: talking about the BAC generation.
Feederle R, Bartlett EJ, Delecluse HJ.
Herpesviridae. 2010 Dec 7;1(1):6.

Busse C, Feederle R, Schnölzer M, Behrends U, Mautner J, Delecluse HJ.
Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.
J Virol. 2010, 8:1139-47.

Hutzinger R, Feederle R, Mrazek J, Schiefermeier N, Balwierz PJ, Zavolan M, Polacek N, Delecluse HJ, Hüttenhofer A.
Expression and processing of a small nucleolar RNA from the Epstein-Barr virus genome.
PLoS Pathog. 2009, 5:e1000547.

Feederle R, Bannert H, Lips H, Müller-Lantzsch N, Delecluse HJ.
The Epstein-Barr virus alkaline exonuclease BGLF5 serves pleiotropic functions in virus replication.
J Virol. 2009, 83:4952-62.

Neuhierl B, Feederle R, Adhikary D, Hub B, Geletneky K, Mautner J, Delecluse HJ.
Primary B cell infection with a ΔBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T cell response.
J Virol. 2009, 83: 4616-23.

Delecluse HJ, Feederle R, Behrends U, Mautner J.
Contributions of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Semin Cancer Biol. 2008, 18: 409-415.

Granato M, Feederle R, Farina A, Gonnella R, Santarelli R, Hub B, Faggioni A, Delecluse HJ.
Deletion of Epstein-Barr virus BFLF2 leads to impaired viral DNA packaging and primary egress as well as to the production of defective viral particles.
J Virol. 2008, 82:4042-51.

Adhikary D, Behrends U, Feederle R, Delecluse HJ, Mautner J.
Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles.
J Virol. 2008, 82: 3903-11

Feederle R, Neuhierl B, Bannert H, Geletneky K, Shannon-Lowe C, Delecluse HJ.
Epstein-Barr virus B95.8 produced in 293 cells shows marked tropism for differentiated primary epithelial cells and reveals inter-individual variation susceptibility to viral infection.
Int. J. Cancer. 2007, 121: 588-94

Feederle R, Neuhierl B, Baldwin G, Bannert H, Hub B, Mautner J, Behrends U, Delecluse HJ.
Epstein-Barr virus BNRF1 protein allows efficient transfer from the endosomal compartment to the nucleus of primary B lymphocytes.
J. Virol. 2006, 80: 9435-43

Feederle R, Shannon-Lowe C, Baldwin G, Delecluse HJ.
Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative Epstein-Barr virus.
J Virol. 2005 79: 7641-7

Neuhierl B & Delecluse HJ.
Molecular Genetics of DNA Viruses in "DNA Viruses: Methods and Protocols, 2004".
Methods Mol Biol. 2004; 292: 353-70

Feederle R & Delecluse HJ.
Low level of lytic replication in a recombinant Epstein-Barr virus carrying an origin of replication devoid of BZLF1 binding sites.
J Virol. 2004; 78:12082-4

Bhende PM, Seaman WT, Delecluse HJ, Kenney SC.
The EBV lytic switch protein Z preferentially binds to and activates the methylated viral genome.
Nat Genet, 2004; 36, 1099-1104

Timms JM, Bell A, Flavell JR, Murray PG, Rickinson AB, Traverse-Glehen A, Berger F, Delecluse HJ.
Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma
Lancet, 2003, 361; 217-23

Neuhierl B, Feederle R, Hammerschmidt H & Delecluse HJ.
Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection.
PNAS, 2002, 99; 15036–15041

HJ Delecluse, M. Kost, W. Hammerschmidt.
An experimental system for the production of infectious particles carrying viral mutants of Kaposi's sarcoma associated virus.
J. Virol. 2001, 75; 2921-2928

Janz, M. Oezel, C. Kurzeder, J. Mautner, D. Pich, M. Kost, W. Hammerschmidt & HJ Delecluse.
An infectious Epstein-Barr virus lacking the major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.
J Virol. 2000, 21; 10142-52

R. Feederle, M. Kost, M. Baumann, A.Janz, E. Drouet, W. Hammerschmidt, & HJ Delecluse.
The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.
EMBO J. 2000, 19; 3080-89

HJ Delecluse, D Pich, T Hilsendegen, C Baum & W Hammerschmidt.
A first-generation packaging cell line for Epstein-Barr virus-derived vectors.
PNAS 1999, 96; 5188-93

HJ Delecluse, T Hilsendegen, D Pich, R Zeidler & W Hammerschmidt.
Propagation and recovery of intact, infectious Epstein-Barr Virus from prokaryotic to human cells.
PNAS 1998, 95; 8245-50

Letzte Aktualisierung: 01.04.2014 Seitenanfang